Transgene Announces Financial Calendar for 2022
06 Janvier 2022 - 05:45PM
Business Wire
Regulatory News:
TRANSGENE (Paris: TNG) today announced its financial
reporting dates for 2022:
March 16, 2022: 2021 Fiscal Year Results
May 10, 2022: First Quarter 2022 Financial Results
May 25, 2022: Annual Shareholders' Meeting
September 14, 2022: First Half 2022 Financial Results
November 7, 2022: Third Quarter 2022 Financial Results
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on
designing and developing targeted immunotherapies for the treatment
of cancer. Transgene’s programs utilize viral vector technology
with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic
vaccines (TG4001 for the treatment of HPV-positive cancers, and
TG4050, the first individualized therapeutic vaccine based on the
myvac® platform) as well as two oncolytic viruses (TG6002 for the
treatment of solid tumors, and BT-001, the first oncolytic virus
based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters
the field of precision medicine with a novel immunotherapy that is
fully tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building
on its viral vector engineering expertise to design a new
generation of multifunctional oncolytic viruses. Transgene has an
ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at:
www.transgene.fr
Follow us on Twitter: @TransgeneSA
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220106005588/en/
Transgene: Jean-Philippe Del Chief Financial
Officer +33 (0)3 88 27 91 00
investorrelations@transgene.fr
Media Transgene: MEDiSTRAVA Consulting David
Dible/Sylvie Berrebi +44 (0)7714 306525
transgene@medistrava.com
Transgene (EU:TNG)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Transgene (EU:TNG)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024